20895-41-4

Usage

Uses

Used in Food Industry:
6-Methyl-3(2H)-benzofuranone is used as a flavor enhancer in various food products for its ability to impart a sweet, caramel-like taste and aroma, enhancing the overall sensory experience of the food items.
Used in Fragrance Industry:
In the fragrance industry, 6-Methyl-3(2H)-benzofuranone is utilized as a fragrance ingredient due to its sweet, caramel-like odor, adding depth and complexity to perfumes and cosmetics.
Used in Pharmaceutical Industry:
6-Methyl-3(2H)-benzofuranone is studied for its potential medicinal properties, such as its antioxidant, anti-inflammatory, and antimicrobial effects, making it a promising candidate for the development of new drugs and treatments.
Used in Cosmetics Industry:
In cosmetics, 6-Methyl-3(2H)-benzofuranone is employed as a fragrance ingredient, leveraging its sweet, caramel-like scent to create appealing and complex fragrances for various cosmetic products.
Overall, 6-Methyl-3(2H)-benzofuranone, or maltol, is a versatile chemical compound with a wide range of applications across different industries, from enhancing the sensory experience in food and fragrances to its potential use in pharmaceutical and cosmetic products.

InChI:InChI=1/C9H8O2/c1-6-2-3-7-8(10)5-11-9(7)4-6/h2-4H,5H2,1H3

Upstream product

• 122-46-3 3-acetoxytoluene 
• 1643-15-8 2-(m-tolyloxy)acetic acid 
• 6921-64-8 4'-hydroxy-2'-methylacetophenone 
• 698-27-1 4-methylsalicylaldehyde 
• 50-85-1 2-hydroxy-p-toluic acid 
• 4670-56-8 methyl 2-hydroxy-4-methylbenzoate 
• 60770-30-1 3-acetoxy-6-methyl-benzofuran 
• 108-39-4 3-methyl-phenol 
• 112920-14-6 2-acetoxy-4-methylacetophenone 
• 144219-74-9 2‐bromo‐1‐(2‐hydroxy‐4‐methylphenyl)ethanone 
• 40926-72-5 2-(m-tolyloxy)acetyl chloride 

Downstream Products

• 142917-39-3 (6-methyl-1-benzofuran-3-yl)acetic acid 
• 143883-37-8 6-Methyl-benzofuran-3-carbaldehyde 
• 1618102-62-7 ethyl 2-(2-(2,4-dichlorophenyl)hydrazono)-2-(6-methyl-3-oxo-2,3-dihydrobenzofuran-2-yl)acetate 
• 1240996-28-4 ethyl ester of 1-(2,4-dichlorophenyl)-6-methyl-1H-benzofuro[3,2-c]pyrazole-3-carboxylic acid 
• 1240998-70-2 1-(2,4-dichlorophenyl)-6-methyl-1H-benzofuro[3,2-0c]pyrazole-3-carboxylic acid 
• 1240996-80-8 N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-6-methyl-1H-benzofuro[3,2-c]pyrazole-3-carbohydrazide 
• 1240996-82-0 N-(pyrrolidin-1-yl)-1-(2,4-dichlorophenyl)-6-methyl-1H-benzofuro[3,2-c]pyrazole-3-carbohydrazide 
• 1240996-83-1 N-(morpholin-1-yl)-1-(2,4-dichlorophenyl)-6-methyl-1H-benzofuro[3,2-c]pyrazole-3-carbohydrazide 
• 1240996-86-4 N-cyclohexyl-1-(2,4-dichlorophenyl)-6-methyl-1H-benzofuro[3,2-c]pyrazole-3-carboxamide 
• 1240997-06-1 N-adamant-2-yl-1-(2,4-dichlorophenyl)-6-methyl-1H-benzofuro[3,2-c]pyrazole-3-carboxamide 
• 1240997-03-8 N-adamant-1-yl-1-(2,4-dichlorophenyl)-6-methyl-1H-benzofuro[3,2-c]pyrazole-3-carboxamide 
• 1618102-57-0 N-menthyl-1-(2,4-dichlorophenyl)-6-methyl-1H-benzofuro[3,2-c]pyrazole-3-carboxamide 
• 1618102-58-1 N-isopinocampheyl-1-(2,4-dichlorophenyl)-6-methyl-1H-benzofuro[3,2-c]pyrazole-3-carboxamide 
• 1618102-59-2 N-bornyl-1-(2,4-dichlorophenyl)-6-methyl-1H-benzofuro[3,2-c]pyrazole-3-carboxamide 

Relevant academic research and scientific papers

MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF

The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

A Palladium-Catalyzed Oxa-(4+4)-Cycloaddition Strategy towards Oxazocine Scaffolds

A Pd-catalyzed oxa-(4+4)-cycloaddition between 1-azadienes and (2-hydroxymethyl)allyl carbonates is described. Aurone-derived azadienes furnished polycyclic 1,5-oxazocines in good yields. Interestingly, linear azadienes have also been involved and yielded monocyclic heterocycles with complete regioselectivity. DFT calculations were carried out to gain insight on this observation.

TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE

The invention provides a variety of compounds having the structure of Formula I and uses of such compounds for treatment of various indications, including cancer as well as methods of treatment involving such compounds are also provided. The uses of the compounds may specifically include: bladder cancer, cholangiocarcinoma; colorectal cancer; diffuse large B-cell lymphoma (DLBC); liver cancer; ovarian cancer; thymoma; thyroid cancer; clear cell renal cell carcinoma (CCRCC); chromophobe renal cell carcinoma (ChRCC); prostate cancer; breast cancer; uterine cancer; pancreatic cancer; cervical cancer; uveal melanoma; acute myeloid leukemia (AML); head and neck cancer; small cell lung cancer (SCLC); lung adenocarcinoma sarcoma; mesothelioma; adenoid cystic carcinoma (ACC), sarcoma; testicular germ cell cancer; uterine cancer; pheochromocytoma and paraganglioma (PCPG); melanoma; glioma; glioblastoma multiforme; T-cell Acute Lymphoblastic Leukemia; T-cell Lympohoma, medulloblastoma; and neuroblastoma.

A Hg(OTf)2-Catalyzed Enolate Umpolung Reaction Enables the Synthesis of Coumaran-3-ones and Indolin-3-ones

The potential of mercury catalysis has been extended to the arena of enolate umpolung reactions for the first time by the generation of enolonium species via Hg(OTf)2-catalyzed N-oxide addition to alkynes. The enolonium species formed can undergo intramolecular nucleophilic attack by hydroxyl or amino groups, leading to the synthesis of various coumaran-3-ones and indolin-3-ones.

Microwave-Assisted Synthesis of Benzofuran-3(2H)-ones

A new method for the synthesis of benzofuran-3(2H)-ones under microwave conditions was developed. The reaction conditions were screened, and the scope of benzoate substrates was investigated. The results showed that our method could provide rapid access to these important dihydrobenzofuranones in 43% to 58% yields.

Total synthesis of the 2-arylbenzo[b]furan-containing natural products from Artocarpus

In this study, 2-arylbenzo[b]furan-containing derivatives moracin C (1) and moracin M (4), the natural products from Artocarpus, have been synthesized in highest overall yield to date (1, 7 steps with an overall yield of 41.9%; 4, 6 steps with an overall yield of 56.3%), and we also report the first total synthesis of artoindonesianin B-1 (2), another member of this family, in the same route (8 steps with an overall yield of 11.3%). This discovery provides a concise route for preparing enough amounts of 1, 2, and 4 as well as 2-arylbenzo[b]furan-containing natural product-like analogs (71-74) to explore the biological potential.

Pharmaceutical compounds wiht angiogenesis inbhibitory activity

Compounds of formula (I): wherein: A, R, T, Q, L, Z, G, X and A' are as defined in the description. B and D, equal to or different from each other, are selected between heteroaryl and aryl, wherein at least one of the hydrogen atoms of said heteroaryl and aryl are substituted with groups selected from SO3-, SO3H, COO-, COOH, and one or more of the other hydrogen atoms of said heteroaryl and aryl are optionally substituted as reported in the description.

PHARMACEUTICAL COMPOUNDS

Compounds of formula (I): wherein: A, R, T, Q, L, Z, G, X and A′ are as defined in the description.B and D, equal to or different from each other, are selected between heteroaryl and aryl, wherein at least one of the hydrogen atoms of said heteroaryl and aryl are substituted with groups selected from SO3?, SO3H, COO?, COOH, and one or more of the other hydrogen atoms of said heteroaryl and aryl are optionally substituted as reported in the description.

PHARMACEUTICAL COMPOUNDS

Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I): wherein the various substituents are as defined in the description. The compounds show affinity for the CB1 and/or CB2 cannabinoidergic receptors.

Tricyclic condensed pyrazole derivatives as CB1 inhibitors

Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring rcomprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous sy